Best Penny Stocks To Watch Now – November 17th

Leap Therapeutics, Autonomix Medical, Cypherpunk Technologies, Annovis Bio, and Datavault AI are the five Penny stocks to watch today, according to MarketBeat’s stock screener tool. Penny stocks are low-priced shares—generally trading below $5 per share in the U.S.—of small or microcap companies that often trade on over-the-counter markets or less-regulated exchanges. They tend to be thinly traded and highly volatile, making them speculative and higher-risk investments that are more susceptible to price manipulation and fraud. These companies had the highest dollar trading volume of any Penny stocks within the last several days.

Leap Therapeutics (LPTX)

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

Autonomix Medical (AMIX)

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.

Cypherpunk Technologies (CYPH)

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.

Annovis Bio (ANVS)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.

Datavault AI (DVLT)

Datavault AI Inc., a data sciences technology company, owns and operates data management and supercomputer platforms. It offers data technology and software solutions. The company was formerly known as WiSA Technologies, Inc. and changed its name to Datavault AI Inc. in February 2025. Datavault AI Inc.